Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United States Cutaneous Squamous Cell Carcinoma Market Introduction Cutaneous Squamous Cell Carcinoma is the second most common form of skin cancers in the U.S. It is attributed to the prolonged exposure to ultraviolet (UV) radiation. These result from the abnormal multiplication of squamous cells in the epidermis and are potentially capable of metastasizing if left untreated. The United States cutaneous squamous cell carcinoma market is aggressively growing because of the rising incidence of skin cancer and improvements in targeted therapies with better response rates in higher percentages of patients and increased awareness regarding early diagnosis. In 2023, there were more than 1.8 million cases of cSCC diagnosed in the U.S., making it a fast-expanding market for treatment options, including surgical procedures, radiation therapy, chemotherapy, and immunotherapy. Recent trends highlight the increasing adoption of checkpoint inhibitors and targeted molecular therapies to enhance treatment outcomes. The market is expected to grow steadily, driven by technological advancements, an aging population, and increased healthcare spending.
Segmentation By Treatment Type • Surgical Procedures o Excisional Surgery Wide Local Excision Mohs Micrographic Surgery Others o Curettage & Electrodesiccation Simple Curettage Advanced Electrosurgical Methods • Radiation Therapy o External Beam Radiation Therapy (EBRT) o Brachytherapy • Systemic Therapy o Chemotherapy Platinum-Based Chemotherapy Others o Immunotherapy PD-1 Inhibitors IL-2 Therapy
By Disease Stage • Localized cSCC o In Situ Carcinoma o Small Lesions • Advanced cSCC o Locally Advanced SCC o Metastatic SCC
By End-User • Hospitals o Academic Medical Centers o Community Hospitals • Specialty Clinics o Dermatology Clinics o Cancer Treatment Centers • Ambulatory Surgical Centers • Research Institutes
By Drug Class • Chemotherapeutics o Fluorouracil (5-FU) o Methotrexate • Targeted Therapies o EGFR Inhibitors o Hedgehog Pathway Inhibitors • Biologics o Immune Checkpoint Inhibitors o PD-1 Blockers
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
List of Market Players 1. Regeneron Pharmaceuticals (USA) 2. Sanofi (France) 3. Merck & Co. (USA) 4. Bristol-Myers Squibb (USA) 5. Eli Lilly and Company (USA) 6. Pfizer Inc. (USA) 7. Novartis AG (Switzerland) 8. AstraZeneca (UK) 9. Roche Holding AG (Switzerland) 10. Amgen Inc. (USA) 11. Sun Pharmaceutical Industries Ltd. (India) 12. Hikma Pharmaceuticals (UK) 13. GlaxoSmithKline (UK) 14. AbbVie Inc. (USA) 15. Takeda Pharmaceutical Company (Japan)
Drivers Few factors are propelling the United States cutaneous squamous cell carcinoma market. The primary driving factor is an increase in cSCC cases, as there are over 1.8 million diagnoses yearly, owing to extended exposure to UV rays. Another driver for this market is an aging population, since more aged patients tend to suffer from cSCC. The increasing use of immunotherapy, especially checkpoint inhibitors such as Cemiplimab (Libtayo) and Pembrolizumab (Keytruda), is changing the course of treatment and improving survival. Advances in molecular diagnostics and AI-driven early detection tools are helping in early diagnosis and personalized treatment strategies. The pipeline of targeted therapies is also strong, along with the rising healthcare expenditure in the U.S., which is driving the growth of the market.
Restraints Despite its growth, the United States cutaneous squamous cell carcinoma market faces some challenges. High treatment costs, especially for immunotherapies, limit patient access. For example, PD-1 inhibitors can cost $150,000+ per year, making them unaffordable for many. Side effects of treatments, including immune-related toxicities and resistance to chemotherapy, also pose challenges. Limited insurance coverage for advanced therapies further hampers market growth. Moreover, in a rural background, the unawareness may lead to delayed diagnosis, which increases the case of mortality. The lack of enough dermatologists and specialists in oncology limits people's access.
Opportunities United States market for cutaneous squamous cell carcinoma offers plenty of opportunities. Increasing government support for skin cancer research and advancement in precision medicine approaches are also fueling the innovation process. Biosimilars for the expensive biologics will further reduce the price and increase its availability. Also, telemedicine and AI-assisted skin cancer screening tools make it possible for early detection. Moreover, co-development of pharmaceutical drugs through collaborations will also facilitate market growth. Companies investing in next-generation targeted therapies and combination treatments will benefit from unmet medical needs in advanced and metastatic cSCC.
Trends Recent trends in the United States cutaneous squamous cell carcinoma market show an increased adoption of minimally invasive treatments such as laser therapy and photodynamic therapy (PDT). Artificial intelligence-assisted diagnostics are revolutionizing early detection by improving accuracy in lesion assessment. The market is also witnessing an increase in clinical trials for combination therapies, particularly PD-1 inhibitors with EGFR inhibitors. The development of biosimilars is another trend providing an antidote to expensive drugs. Moreover, consumer demand in such preventive care for skin and its protection from UV rays also affects the broader landscape of the prevention of skin cancer.
Key Target Audience • Pharmaceutical & Biotechnology Companies • Oncology Research Institutes • Dermatology Clinics & Hospitals • Cancer Treatment Centers • Government Health Agencies • Investors & Venture Capitalists • Health Insurance Companies
Frequently Asked Questions (FAQ's)
The market is driven by the rising incidence of cSCC, advancements in immunotherapy, and early diagnosis technologies.
Treatment includes surgery (Mohs, excision), radiation, chemotherapy, targeted therapy, and immunotherapy (PD-1 inhibitors).
Key players include Regeneron, Merck & Co., Sanofi, Bristol-Myers Squibb, Pfizer, and Novartis.
High treatment costs, limited insurance coverage, and lack of early diagnosis in underserved regions pose challenges.
The market is expected to grow steadily due to increasing awareness, new drug approvals, and innovation in treatment methods.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Treatment Types 3.2.2 By Disease Stage 3.2.3 By End-User 3.2.4 By Drug Class 3.2.5 By Distribution Channel 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United States Cutaneous Squamous Cell Carcinoma Market by Treatment Types 4.1 Introduction 4.2 Market Size and Growth Rate by Treatment Types (2024-2030) 4.2.1 Surgical Procedures 4.2.1.1 Excisional Surgery 4.2.1.2 Mohs Micrographic Surgery 4.2.1.3 Curettage & Electrodesiccation 4.2.2 Radiation Therapy 4.2.2.1 External Beam Radiation Therapy (EBRT) 4.2.2.2 Brachytherapy 4.2.3 Systemic Therapy 4.2.3.1 Chemotherapy 4.2.3.2 Immunotherapy 4.2.4 Targeted Therapy 4.2.4.1 Epidermal Growth Factor Receptor (EGFR) Inhibitors 4.2.4.2 Hedgehog Pathway Inhibitors
5. United States Cutaneous Squamous Cell Carcinoma Market by Disease Stage 5.1 Introduction 5.2 Market Size and Growth Rate by Disease Stage (2024-2030) 5.2.1 Localized cSCC 5.2.1.1 In Situ Carcinoma 5.2.1.2 Small Lesions 5.2.2 Advanced cSCC 5.2.2.1 Locally Advanced SCC 5.2.2.2 Metastatic SCC
6. United States Cutaneous Squamous Cell Carcinoma Market by End-User 6.1 Introduction 6.2 Market Size and Growth Rate by End-User (2024-2030) 6.2.1 Hospitals 6.2.1.1 Academic Medical Centers 6.2.1.2 Community Hospitals 6.2.2 Specialty Clinics 6.2.2.1 Dermatology Clinics 6.2.2.2 Cancer Treatment Centers 6.2.3 Ambulatory Surgical Centers 6.2.4 Research Institutes
7. United States Cutaneous Squamous Cell Carcinoma Market by Drug Class 7.1 Introduction 7.2 Market Size and Growth Rate by Drug Class (2024-2030) 7.2.1 Chemotherapeutics 7.2.1.1 Fluorouracil (5-FU) 7.2.1.2 Methotrexate 7.2.2 Targeted Therapies 7.2.2.1 EGFR Inhibitors 7.2.2.2 Hedgehog Pathway Inhibitors 7.2.3 Biologics 7.2.3.1 PD-1 Blockers 7.2.3.2 Immune Checkpoint Inhibitors
8. United States Cutaneous Squamous Cell Carcinoma Market by Distribution Channel 8.1 Introduction 8.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 8.2.1 Hospital Pharmacies 8.2.1.1 Oncology Pharmacies 8.2.1.2 General Hospital Pharmacies 8.2.2 Retail Pharmacies 8.2.2.1 Independent Pharmacies 8.2.2.2 Chain Pharmacies 8.2.3 Online Pharmacies
9. Competitive Landscape 9.1 Company Profiles 9.1.1 Regeneron Pharmaceuticals (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.2 Sanofi (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.3 Merck & Co. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.4 Bristol-Myers Squibb (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.5 Eli Lilly and Company (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.6 Pfizer Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.7 Novartis AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.8 AstraZeneca (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.9 Roche Holding AG (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.10 Amgen Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.11 Sun Pharmaceutical Industries Ltd. (India) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.12 Hikma Pharmaceuticals (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.13 GlaxoSmithKline (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.14 AbbVie Inc. (United States) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9.1.15 Takeda Pharmaceutical Company (Japan) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview
10. Conclusion and Recommendations
11. Appendix 11.1 List of Tables • Table 1: United States cSCC Market Size & Growth Rate (2024-2030) • Table 2: Segmentation by Treatment Type, Disease Stage, and End-Users • Table 3: Competitive Landscape – Market Share of Key Players • Table 4: Approved & Pipeline Products in the Market
11.2 List of Figures • Figure 1: Market Share by Treatment Type (2024) • Figure 2: Market Distribution by End-User (2024) • Figure 3: Market Growth Forecast by Drug Class (2024-2030) • Figure 4: Competitive Analysis of Key Market Players
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United States market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United States Cutaneous Squamous Cell Carcinoma Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United States Cutaneous Squamous Cell Carcinoma Market for the past year and forecasts for the next six years. United States Cutaneous Squamous Cell Carcinoma Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United States Cutaneous Squamous Cell Carcinoma Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United States Cutaneous Squamous Cell Carcinoma Market from different application industries in different regions.
Segmentation By Treatment Type • Surgical Procedures o Excisional Surgery Wide Local Excision Mohs Micrographic Surgery Others o Curettage & Electrodesiccation Simple Curettage Advanced Electrosurgical Methods • Radiation Therapy o External Beam Radiation Therapy (EBRT) o Brachytherapy • Systemic Therapy o Chemotherapy Platinum-Based Chemotherapy Others o Immunotherapy PD-1 Inhibitors IL-2 Therapy
By Disease Stage • Localized cSCC o In Situ Carcinoma o Small Lesions • Advanced cSCC o Locally Advanced SCC o Metastatic SCC
By End-User • Hospitals o Academic Medical Centers o Community Hospitals • Specialty Clinics o Dermatology Clinics o Cancer Treatment Centers • Ambulatory Surgical Centers • Research Institutes
By Drug Class • Chemotherapeutics o Fluorouracil (5-FU) o Methotrexate • Targeted Therapies o EGFR Inhibitors o Hedgehog Pathway Inhibitors • Biologics o Immune Checkpoint Inhibitors o PD-1 Blockers
By Distribution Channel • Hospital Pharmacies • Retail Pharmacies • Online Pharmacies
